XTLB (XTL Biopharmaceuticals) Effective Interest Rate on Debt %: -49.58% (As of Dec. 2025)


XTLB XTL Biopharmaceuticals Ltd XTLB
26 GF Score
Price $2.91
! 4 Warning Signs
View Full Analysis

What is XTL Biopharmaceuticals Effective Interest Rate on Debt %?

XTL Biopharmaceuticals XTLB +0.69% 26 Effective Interest Rate on Debt % is -49.58% as of Dec. 2025. GuruFocus rates XTLB with a GF Score™ of 26/100. The stock has 4 warning signs investors should review.

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. XTL Biopharmaceuticals's annualized positive value of Interest Expense for the quarter that ended in Dec. 2025 was $-0.09 Mil. XTL Biopharmaceuticals's average total debt for the quarter that ended in Dec. 2025 was $0.18 Mil. Therefore, XTL Biopharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2025 was -49.58%.


XTL Biopharmaceuticals  (NAS:XTLB) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


XTL Biopharmaceuticals Effective Interest Rate on Debt % Related Terms


XTL Biopharmaceuticals Effective Interest Rate on Debt % Historical Data

* Premium members only.

The historical data trend for XTL Biopharmaceuticals's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XTL Biopharmaceuticals Effective Interest Rate on Debt % Chart

XTL Biopharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 20.29 3.44

XTL Biopharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -1.45 91.07 -49.58

XTLB vs VRTX, REGN, ALNY: Effective Interest Rate on Debt % Comparison

For the Biotechnology subindustry, XTL Biopharmaceuticals's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XTL Biopharmaceuticals Effective Interest Rate on Debt % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where XTL Biopharmaceuticals's Effective Interest Rate on Debt % falls into.


XTLB
26GF Score
XTL Biopharmaceuticals Ltd XTLB
Effective Interest Rate on Debt % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XTL Biopharmaceuticals Effective Interest Rate on Debt % Calculation

XTL Biopharmaceuticals's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2024 )+Total Debt  (A: Dec. 2025 ))/ count )
=-1  *  -0.007/( (0.138+0.269)/ 2 )
=-1  *  -0.007/0.2035
=3.44 %

where

XTL Biopharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Jun. 2025 )+Total Debt  (Q: Dec. 2025 ))/ count )
=-1  *  0.088/( (0.086+0.269)/ 2 )
=-1  *  0.088/0.1775
=-49.58 %

where

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is two times the semi-annual (Dec. 2025) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

What does a Effective Interest Rate on Debt % of -49.58% mean?
XTL Biopharmaceuticals (XTLB) has a Effective Interest Rate on Debt % of -49.58% as of Dec. 2025. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on XTL Biopharmaceuticals and its competitors.
Is XTL Biopharmaceuticals' Effective Interest Rate on Debt % too high?
XTL Biopharmaceuticals' current Effective Interest Rate on Debt % is -49.58%. Overall, XTL Biopharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does XTL Biopharmaceuticals' Effective Interest Rate on Debt % compare to VRTX and REGN?
XTL Biopharmaceuticals' Effective Interest Rate on Debt % of -49.58% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Biotechnology company?
A good Effective Interest Rate on Debt % depends on the Biotechnology industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on XTL Biopharmaceuticals and its competitors. XTL Biopharmaceuticals's current Effective Interest Rate on Debt % is -49.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XTL Biopharmaceuticals stock overvalued right now?
XTL Biopharmaceuticals (XTLB) has a current Effective Interest Rate on Debt % of -49.58%. The current Effective Interest Rate on Debt % is -49.58%. XTL Biopharmaceuticals' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For XTL Biopharmaceuticals (XTLB), the current Effective Interest Rate on Debt % is -49.58% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XTL Biopharmaceuticals Business Description

Other Exchanges XTLB:IsraelHHB0:Germany
Address 26 Ben-Gurion Street, Ramat Gan, ISR, 5112001
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
26GF Score

Get the complete analysis for XTLB

Effective Interest Rate on Debt % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.91
Price